An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Overview of attention for article published in European Journal of Cancer (1965), September 2018

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 4 X users

Readers on

mendeley: 37 Mendeley

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 4,488 followers.

Open Access UCL Research: An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours https://t.co/fiIm2VWI0J

Prof Ruth Plummer collaborates with more scientists - read more here An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. https://t.co/sr9KrhEXs2 #research #scienc…

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. https://t.co/IMXg1uQ6cF

#newupdatesneuroonc #oncology An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours https://t.co/shUYCrWsLl

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.